STOCKHOLM, Feb. 14, 2020 /PRNewswire/ -- Fourth
Quarter
- Revenue increased by 26.8% to €229.7m (€181.2m). Organic
revenue grew by 15.0%.
- Operating profit (EBIT) increased by 26.6% to €10.8m (€8.6m),
representing an operating margin of 4.7% (4.7%).
- Net profit amounted to €6.6m (€3.5m), which represents a net
profit margin of 2.9% (1.9%).
- EBITDA increased by 37.5% to €33.4m (€24.3m), corresponding to
an EBITDA margin of 14.5% (13.4%).
- EBITDAaL increased by 40.5% to €22.3m (€15.9m), corresponding
to an EBITDAaL margin of 9.7% (8.8%).
- Net cash flow from operating activities was €25.0m
(€16.6m).
- Medicover Hospitals India (former MaxCure) consolidated as of 1
December.
- Basic/diluted earnings per share were €0.048 (€0.022).
Full Year
- Revenue increased by 25.7% to €844.4m (€671.6m). Organic
revenue grew by 14.8%.
- Operating profit (EBIT) increased by 38.0% to €46.5m (€33.7m),
representing an operating margin of 5.5% (5.0%).
- Net profit amounted to €24.7m (€24.2m), which represents a net
profit margin of 2.9% (3.6%) affected by lower other
income/costs.
- EBITDA increased by 33.0% to €120.7m (€90.7m), corresponding to
an EBITDA margin of 14.3% (13.5%), impacted by €2.4m (€1.8m) merger
and acquisition related costs expensed.
- EBITDAaL increased by 37.7% to €80.6m (€58.5m), corresponding
to an EBITDAaL margin of 9.5% (8.7%).
- Net cash flow from operating activities amounted to €87.3m
(€74.4m).
- Basic/diluted earnings per share were €0.168 (€0.167).
- The board of directors proposes a dividend for 2019 of €0.05
per share.
REVENUE AND EARNINGS
|
€ millions
(€m)
|
Q4
2019
|
Q4
2018
|
Growth
|
FY
2019
|
FY
2018
|
Growth
|
|
Revenue
|
229.7
|
181.2
|
27%
|
844.4
|
671.6
|
26%
|
|
Operating profit
(EBIT)
|
10.8
|
8.6
|
27%
|
46.5
|
33.7
|
38%
|
|
Operating profit
margin, %
|
4.7%
|
4.7%
|
|
5.5%
|
5.0%
|
|
|
Net profit
|
6.6
|
3.5
|
91%
|
24.7
|
24.2
|
2%
|
|
Net profit margin,
%
|
2.9%
|
1.9%
|
|
2.9%
|
3.6%
|
|
|
Basic/diluted
earnings per share, €
|
0.048
|
0.022
|
118%
|
0.168
|
0.167
|
1%
|
|
|
|
|
|
|
|
|
EBITDA
|
33.4
|
24.3
|
37%
|
120.7
|
90.7
|
33%
|
|
EBITDA margin,
%
|
14.5%
|
13.4%
|
|
14.3%
|
13.5%
|
|
|
EBITDAaL
|
22.3
|
15.9
|
40%
|
80.6
|
58.5
|
38%
|
|
EBITDAaL margin,
%
|
9.7%
|
8.8%
|
|
9.5%
|
8.7%
|
|
|
EBITA
|
13.9
|
10.0
|
39%
|
53.7
|
37.0
|
45%
|
|
EBITA margin,
%
|
6.0%
|
5.5%
|
|
6.4%
|
5.5%
|
|
For definition and reconciliation of alternative performance
measures, refer to note 10. As from Q3 2019 margins (including
margins of comparative figures) and growth rates have been
calculated based on EUR whole figures instead of figures rounded in
millions.
This is information that Medicover AB is obliged to make public
pursuant to the EU Market Abuse Regulation and the Securities
Markets Act. The information was submitted for publication through
the agency of the contact person set out below at 7.45 (CET) on
14 February 2020. This interim report
and other information about Medicover is available at
medicover.com.
Medicover is a leading international healthcare and diagnostic
services company and was founded in 1995. Medicover operates a
large number of ambulatory clinics, hospitals, specialty-care
facilities and laboratories and the largest markets are
Poland and Germany. In 2018, Medicover had revenue around
€672 million and 20,970 employees. For more information, go to
www.medicover.com
For further information, please contact:
Hanna Bjellquist, Head of Investor
Relations
Phone: +46-70-303-3272
hanna.bjellquist@medicover.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medicover/r/year-end-report-january-december-2019,c3035280
The following files are available for download:
|
https://mb.cision.com/Main/15662/3035280/1193827.pdf
|
Year-end report
January-December 2019
|